Neuro Spectrum Insights, Inc. IPO — what the S-1 filing reveals | StockTools

ipo radar // reading the prospectusLOADING

Neuro Spectrum Insights, Inc.

Registered to go public · latest filing S-1/A on 2026-07-10

what the prospectus reveals // AI read of the S-1

NeuroSpectrum Insights is a pre-revenue medical device company that has developed GyriCalc, a patented software tool that automatically measures brain structure (gyrification) from standard MRI scans to help clinicians diagnose autism and speed access to treatment. It plans to make money by commercializing GyriCalc in the U.S. and Canada, though the filing states it currently generates no revenue and its first product has not yet received FDA clearance for diagnostic use.

Financials: The filing clearly states the company currently generates no revenue and incurred net losses of approximately $2,649,000 (2024), $1,826,000 (2025), and $521,467 (Q1 2026), with an accumulated deficit of $7,677,091 as of March 31, 2026.

Use of proceeds: Not specified in the provided text (the Use of Proceeds section is referenced on page 45 but its contents are not included in this excerpt).

strengths it claims

The company states GyriCalc received FDA 510(k) marketing clearance in July 2025 via an expedited pathway, which it presents as validation of the technology's functional brain-measurement capabilities.
It holds an exclusive worldwide license to the underlying technology from the University of Louisville, which the filing frames as proprietary and patented.
The company claims GyriCalc could dramatically shorten time-to-diagnosis by delivering objective, data-driven results, addressing a stated need in autism diagnostics.
Management notes academic research suggests the underlying technology could potentially extend to other conditions such as dyslexia, ADHD, or schizophrenia, though it states it has no current plans to pursue these.

risks it discloses

The company generates no revenue at all and has an accumulated deficit of roughly $7.7 million as of March 31, 2026, with continued net losses ($2.6M, $1.8M, and $0.5M in the most recent periods).
Despite 510(k) marketing clearance, GyriCalc has NOT received FDA clearance for diagnostic use, which the filing repeatedly emphasizes as a key limitation on commercialization.
There is a disclosed conflict of interest: Damon D. Testaverde is both a director/officer of the sole book-running underwriter (Network 1 Financial Securities) and a principal shareholder of the company.
The offering is contingent on NYSE American listing approval, which the filing says is not assured; if not approved, the offering will not proceed.
The company relies on a single, still-uncommercialized product validated by a small 84-subject clinical study, and faces uncertain regulatory, reimbursement, and market-entry timelines in both the U.S. and Canada.

⚠ This is a pre-revenue, deeply loss-making company whose sole product has FDA marketing clearance but not diagnostic-use clearance, and whose offering carries a disclosed conflict of interest involving its lead underwriter and a principal shareholder.

The AI read is generated from the company’s own SEC S-1/424B prospectus and may miss nuance — read the filing before relying on it. A prospectus is written to sell the offering. An S-1 registration doesn’t guarantee an IPO will happen, or when. Educational only, not financial advice, and never a recommendation to buy or sell.